CO2021010930A2 - Hidroxipiridoxazepinas como activadores de nrf2 - Google Patents
Hidroxipiridoxazepinas como activadores de nrf2Info
- Publication number
- CO2021010930A2 CO2021010930A2 CONC2021/0010930A CO2021010930A CO2021010930A2 CO 2021010930 A2 CO2021010930 A2 CO 2021010930A2 CO 2021010930 A CO2021010930 A CO 2021010930A CO 2021010930 A2 CO2021010930 A2 CO 2021010930A2
- Authority
- CO
- Colombia
- Prior art keywords
- hydroxypyridoxazepines
- nrf2
- activators
- nrf2 activators
- tautomers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
La presente invención se refiere a compuestos de hidroxipiridoxazepina, métodos para prepararlos, composiciones farmacéuticas que los contienen y su uso como activadores de Nrf2.o una de sus sales, particularmente una de sus sales farmacéuticamente aceptables, o uno de sus tautómeros, o uno de sus hidratos. Composiciones farmacéuticas que los contienen y su uso como activadores de Nrf2. En particular, la invención se refiere a compuestos de Fórmula (I) y sus sales farmacéuticamente aceptables, o uno de sus tautómero o uno de sus hidratos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962806201P | 2019-02-15 | 2019-02-15 | |
| US201962931877P | 2019-11-07 | 2019-11-07 | |
| PCT/IB2020/051100 WO2020165776A1 (en) | 2019-02-15 | 2020-02-11 | Hydroxypyridoxazepines as nrf2 activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021010930A2 true CO2021010930A2 (es) | 2021-09-09 |
Family
ID=69726636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0010930A CO2021010930A2 (es) | 2019-02-15 | 2021-08-19 | Hidroxipiridoxazepinas como activadores de nrf2 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11945826B2 (es) |
| EP (1) | EP3924356A1 (es) |
| JP (1) | JP2022520442A (es) |
| KR (1) | KR20210126676A (es) |
| CN (1) | CN113474349B (es) |
| AU (1) | AU2020222080C1 (es) |
| BR (1) | BR112021016042A2 (es) |
| CA (1) | CA3129955A1 (es) |
| CL (1) | CL2021002110A1 (es) |
| CO (1) | CO2021010930A2 (es) |
| IL (1) | IL285438A (es) |
| MA (1) | MA54939A (es) |
| MX (1) | MX2021009659A (es) |
| SG (1) | SG11202108257TA (es) |
| TW (1) | TW202045514A (es) |
| WO (1) | WO2020165776A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3833662T3 (da) | 2018-08-20 | 2024-02-26 | Janssen Pharmaceutica Nv | Inhibitorer af protein-protein-interaktionen mellem KEAP-1-NRF2- |
| AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
| WO2023210741A1 (ja) * | 2022-04-28 | 2023-11-02 | 第一三共株式会社 | ベンゾトリアゾール化合物 |
| WO2023210740A1 (ja) * | 2022-04-28 | 2023-11-02 | 第一三共株式会社 | ベンゾチオフェン化合物 |
| WO2024047248A1 (en) * | 2022-09-02 | 2024-03-07 | Institut National de la Santé et de la Recherche Médicale | Use of nrf2 activators for the treatment of cerebral small vessel disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2094651A1 (en) * | 2006-11-17 | 2009-09-02 | Trustees Of Dartmouth College | Synthesis and biological activities of new tricyclic-bis-enones (tbes) |
| CN105829305B (zh) | 2013-12-18 | 2018-11-30 | 葛兰素史密斯克莱知识产权发展有限公司 | Nrf2调节剂 |
| CN108112251B (zh) * | 2015-06-15 | 2021-03-05 | 葛兰素史克知识产权发展有限公司 | Nrf2调节剂 |
| KR20180017038A (ko) | 2015-06-15 | 2018-02-20 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Nrf2 조절제 |
| EP3307729B1 (en) | 2015-06-15 | 2020-09-02 | GlaxoSmithKline Intellectual Property Development Limited | Nrf2 regulators |
| US10201531B2 (en) * | 2015-08-12 | 2019-02-12 | Mochida Pharmaceutical Co., Ltd. | Indazolyl-oxo-isothiazole compounds |
| US10364256B2 (en) * | 2015-10-06 | 2019-07-30 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as NRF2 regulators |
| WO2018104766A1 (en) | 2016-12-06 | 2018-06-14 | Glaxosmithkline Intellectual Property Development Limited | 3-(2,3-dihydro-1h-inden-5-yl)propanoic acid derivatives and their use as nrf2 regulators |
| JP2020500918A (ja) * | 2016-12-12 | 2020-01-16 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎｒｆ２レギュレーターとしてのｎ−アリールピラゾール |
| JP2020502136A (ja) * | 2016-12-14 | 2020-01-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎｒｆ２レギュレーターとしてのビスアリールアミド |
| BR112019012300A2 (pt) | 2016-12-15 | 2019-11-12 | Glaxosmithkline Ip Dev Ltd | ativadores nrf2 |
-
2020
- 2020-02-11 MX MX2021009659A patent/MX2021009659A/es unknown
- 2020-02-11 BR BR112021016042-6A patent/BR112021016042A2/pt unknown
- 2020-02-11 US US17/429,088 patent/US11945826B2/en active Active
- 2020-02-11 EP EP20708180.3A patent/EP3924356A1/en active Pending
- 2020-02-11 WO PCT/IB2020/051100 patent/WO2020165776A1/en unknown
- 2020-02-11 CA CA3129955A patent/CA3129955A1/en active Pending
- 2020-02-11 AU AU2020222080A patent/AU2020222080C1/en active Active
- 2020-02-11 MA MA054939A patent/MA54939A/fr unknown
- 2020-02-11 KR KR1020217029193A patent/KR20210126676A/ko unknown
- 2020-02-11 JP JP2021547429A patent/JP2022520442A/ja active Pending
- 2020-02-11 CN CN202080014726.4A patent/CN113474349B/zh active Active
- 2020-02-11 SG SG11202108257TA patent/SG11202108257TA/en unknown
- 2020-02-13 TW TW109104455A patent/TW202045514A/zh unknown
-
2021
- 2021-08-08 IL IL285438A patent/IL285438A/en unknown
- 2021-08-11 CL CL2021002110A patent/CL2021002110A1/es unknown
- 2021-08-19 CO CONC2021/0010930A patent/CO2021010930A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021016042A2 (pt) | 2021-10-05 |
| TW202045514A (zh) | 2020-12-16 |
| AU2020222080B2 (en) | 2022-05-19 |
| MA54939A (fr) | 2021-12-22 |
| CN113474349A (zh) | 2021-10-01 |
| MX2021009659A (es) | 2021-09-08 |
| US11945826B2 (en) | 2024-04-02 |
| EP3924356A1 (en) | 2021-12-22 |
| SG11202108257TA (en) | 2021-08-30 |
| AU2020222080A1 (en) | 2021-09-02 |
| CL2021002110A1 (es) | 2022-02-11 |
| AU2020222080C1 (en) | 2022-09-29 |
| WO2020165776A1 (en) | 2020-08-20 |
| US20220204526A1 (en) | 2022-06-30 |
| JP2022520442A (ja) | 2022-03-30 |
| CN113474349B (zh) | 2024-03-01 |
| IL285438A (en) | 2021-09-30 |
| KR20210126676A (ko) | 2021-10-20 |
| CA3129955A1 (en) | 2020-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI202000078A (es) | Compuestos heteroaril tetracíclicos | |
| CO2021010930A2 (es) | Hidroxipiridoxazepinas como activadores de nrf2 | |
| AR121273A2 (es) | Inhibidores enzimáticos para uso en medicina y composición farmacéutica que los comprende | |
| CL2018000730A1 (es) | Compuestos heterocíclicos y usos de los mismos | |
| CL2017001675A1 (es) | Derivados de quinazolina utilizados para tratar el vih | |
| ECSP12012334A (es) | Morfolinopirimidinas y su uso en terapia | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| SV2011003970A (es) | Derivados de sulfonamida | |
| DOP2018000062A (es) | Piridinona dicaboxamidas para uso como inhibidores de bromodominio | |
| DOP2014000036A (es) | Compuestos de piridazinona y su uso como inhibidores daao | |
| ECSP088584A (es) | Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl) | |
| AR101414A1 (es) | Derivados de pirrolidinona como inhibidores de metap-2 | |
| CO2020004977A2 (es) | Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa | |
| CL2019001991A1 (es) | Moduladores del receptor de estrógeno. | |
| UY37191A (es) | Derivados de dibenzofurano para uso como inhibidores de bromodominio | |
| UY32635A (es) | Derivados de bis-(sulfonilamino) en terapia 735 | |
| UY38759A (es) | Tienilhidroxiisoxazolinas y derivados de las mismas | |
| UY37551A (es) | Activador de nrf2 | |
| CO2018007610A2 (es) | Derivados de indano y su uso en terapias | |
| ECSP13012372A (es) | Nuevos derivados 1,4-diazepanos, inhibidores de pde-5. | |
| CL2020000439A1 (es) | Sales de un compuesto y sus formas cristalinas. | |
| CL2019003236A1 (es) | Las sales de un compuesto y sus formas cristalinas. | |
| UY38758A (es) | Hidroxiisoxazolinas y derivados de las mismas | |
| UY38764A (es) | Hidroxiisoxazolinas y derivados de las mismas |